Modality
Radioligand
MOA
HER2
Target
IL-13
Pathway
Apoptosis
PAHADPKD
Development Pipeline
Preclinical
~Jun 2013
→ ~Sep 2014
Phase 1
~Dec 2014
→ ~Mar 2016
Phase 2
~Jun 2016
→ ~Sep 2017
Phase 3
Dec 2017
→ Dec 2031
Phase 3Current
NCT06473432
2,949 pts·ADPKD
2025-05→2031-12·Not yet recruiting
NCT06957881
22 pts·ADPKD
2019-12→TBD·Terminated
NCT05367108
909 pts·ADPKD
2017-12→2027-12·Active
+1 more trial
4,956 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-12-151.7y awayPh3 Readout· ADPKD
2031-12-245.7y awayPh3 Readout· ADPKD
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Active
P3
Termina…
P3
Termina…
P3
Not yet…
Catalysts
Ph3 Readout
2027-12-15 · 1.7y away
ADPKD
Ph3 Readout
2031-12-24 · 5.7y away
ADPKD
ActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06473432 | Phase 3 | ADPKD | Not yet recr... | 2949 | 6MWD |
| NCT06957881 | Phase 3 | ADPKD | Terminated | 22 | DOR |
| NCT05367108 | Phase 3 | ADPKD | Active | 909 | eGFR |
| NCT06618965 | Phase 3 | PAH | Terminated | 1076 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 |